

**Schedules to the
Asset Purchase Agreement
by and between
deCODE genetics, Inc.
and
Saga Investments LLC**

Schedule 1.1(a) - Equity or Other Ownership Interests of Seller in the Iceland Entities

Schedule 1.1(b) - Business Intellectual Property

Schedule 1.1(i) - Assigned Contracts

Schedule 1.1(m) - Seller and U.S. Subs Amounts Receivable Arising from Completed,
Unbilled Work in Process Related to the Assigned Contracts

Schedule 1.1(s) - Other Assets Related to the Business

Schedule 1.2(c) - Excluded Intellectual Property

Schedule 1.2(r) - Persons to be Hired by Purchaser, its Affiliates or the Iceland Entities

Schedule 1.2(s) - Excluded Property and Assets

Schedule 4.7 - Capitalization of Purchaser

Schedule 6.5(a) - Potentially Assigned Seller Contracts

Schedule 6.8(b) - Transfer of Assets

Schedule 6.8(c) - Termination of Material Contracts

Schedule 6.8(j) - Employment Agreements

Schedule 6.19 - Contract Termination

Schedule 7.2(n) - Amounts Owed to Major Creditors

Schedule 7.2(o)-1 - Continuing Employees of Iceland Sub

Schedule 7.2(o)-2 - Continuing Employees of Seller and U.S. Subs

SCHEDULE 1.1(A)
Equity or Other Ownership Interests of Seller in the Iceland Entities

Seller owns 100% of the share capital of Islensk erfdagreining ehf (“IE”). (English name: deCODE genetics ehf), nominal value ISK 2,000,000,000.

IE owns 100% of the share capital of Urdur, Verdandi Skuld –UVS, nominal value ISK 4,370,000.

SCHEDULE 1.1(b)
Business Intellectual Property

Please see (i) the list of Registered IP disclosed in Exhibit A to the Seller Disclosure Schedule (the supplement to Section 5.21(b) of the Seller Disclosure Schedule) and (ii) Section 5.21(m) of the Seller Disclosure Schedule regarding proprietary software.

SCHEDULE 1.1(i)
Assigned Contracts

The following list is preliminary and is to be finalized by the Contract Determination Date:

License Agreement [relating to diabetes-related pathologies and metabolic syndrome] between deCODE genetics, Inc. and deCODE genetics, ehf, and Celera Corporation, effective April 22, 2009.

License Agreement [relating to cardiovascular and vascular diseases] between deCODE genetics, Inc. and deCODE genetics, ehf, and Celera Corporation, effective April 22, 2009.

[Collaboration and Cross-License Agreement among Hoffman-La Roche Inc., F.Hoffman-La Roche Ltd., deCODE genetics, Inc., and Islensk erfdagreining ehf., dated February 1, 1998.]

[Research Collaboration and License Agreement between Merck & Co., deCODE genetics, Inc. and deCODE genetics, ehf., effective September 26, 2002, as amended by [First Amendment?], and Second Amendment, effective September 29, 2004.]

[Agreement for the Transfer of Research Materials between The University Court of the University of Aberdeen and Grampian Health Board, and Decode Genetics Inc., dated July 10, 2009.]

[Master Project Agreement between deCODE genetics, Inc. and Fisher Clinical Services Inc., dated March 17, 2005.]

[Pharmaceutical Contract Services Agreement between deCODE chemistry, Inc. and BioConvergence LLC, effective April 20, 2007.]

[Toxicology Services Agreement between deCODE Chemistry, Inc. and Experimur, dated September 6, 2005.]

[Memorandum of Understanding among the Regents of the University of New Mexico, for its public operation known as the Health Sciences Center, deCode Genetics, Inc., and the National Center for Genome Resources, effective January 14, 2004.]

[Agreement for the Transfer of Research Materials between The University Court of the University of Aberdeen and Grampian University Hospitals NHS Trust, and Decode Genetics Inc., dated [____] 2006.]

[Material Transfer Agreement between Drs. Richard Mains and Betty Eiper, with laboratory at University of Connecticut Health Center, and deCODE Genetics, Inc., effective December 9, 2003.]

SCHEDULE 1.1(m)

Seller and U.S. Subs Amounts Receivable Arising from Completed, Unbilled Work in Process Related to the Assigned Contracts

[To be completed following finalization of Schedule 1.1(i) (Assigned Contracts) following Contract Determination Date]

SCHEDULE 1.1(s)
Other Assets Related to the Business

None

SCHEDULE 1.2(c)
Excluded Intellectual Property

(i) *Common law trademarks and service marks*

MPCS Microcapillary Protein Crystallization System
DETECT-X
Peel Apart
Diffraction Ready
Matrix Maker
Drop Maker
Protein Maker
Plug Maker
CrysTEL
Crystal Monitor
Crystal Miner
Clover Plates
Wizard
Cryo
Peg Anomalous
Precipitant Synergy
Phat Screen
Ozma
Cubic
SLIC Structure-Lead-IND
96i

(ii) *Registered trademarks, service marks and trade names and applications*

Gene Composer	Reg No. 3652895 (Supp Register)	Registration Date: July 7, 2009
Fragments of Life	Reg No. 3623367	Registration Date: May 19, 2009
Crystal Ready	Application Serial No. 77,138,622	Proof of Use needed, next date: 12/18/09
ParaSOL	Application Serial No. 78/649,975	Proof of Use needed, next date: 12/18/09
Crystal Card	Application Serial No. 77/519,931	Published for Opposition, May 5, 2009
RapidSeal	Application Serial No. 77/519,975	Published for Opposition, May 12, 2009

(iii) *Registered copyrights and applications*

None.

(iv) *Patents, patent applications and invention disclosures*

Method and a System for Automating the Execution of AMoRe Over a Heterogeneous Network of Computers	U.S. Pat. No. 7,203,683 B2 PCT/US2002/032642
Screening Methods for Identifying Ligands	U.S. Pat. No. 6,950,757 B2 PCT/US02/11552+ GB 2 391 941+
Capillary Crystallization System	U.S. App. No. 12/484983

Method and System for Creating a Crystallization Results Database	U.S. Pat. No. 6,811,608 B1 PCT/US00/21043 EP 1206697
Crystallization Tray	U.S. Pat. No. 6039804 PCT/US99/19500 EP 1119654 Japan 2000-569044+ Canada 2,343,739 United Kingdom 9994241.4 Sweden 9994241.4 Netherlands 9994241.4 Austria 9994241.4 France 9994241.4 Germany 9994241.4
Crystallization Solutions	U.S. Pat. No. 6,599,441 B1 PCT/US1999/014390 (WO/2000/000678)+ 11/171,640+
Systems and Methods for Generating Images of Crystals	US Pat. No. 7,462,237 PCT/US2005/023 232 Canada 2,571,119 EP 5768699.0 Japan 2007-519421 Japan 2007-517421
Gene Synthesis Software	U.S. Pat. No. 7587284 PCT/US2006/002 278 Europe 6719226
Systems and Methods for Dispensing Portions of Viscous Material	U.S. Pat. No 7,610,943 PCT/US05/20439 (WO05122728)+
Robot For Mixing Crystallization Matrices	U.S. Pat. No. 6,818,060 B2 PCT/US02/20953 EP 2746819.8 EP1399605
Nanovolume Microcapillary Crystallization System	U.S. App. No. 12/484983 PCT/US2009/047414
Apparatus for Microfluidic Molecule Crystallization Removal and Processing	U.S. App. No. 61/187234
Structures and Methods for Designing Topoisomerase I	PCT/US01/43550 (WO0240653)+ Europe 1335974 (Withdrawn)+ Australia 219815+ U.S. App. No. 60/248,474+ U.S. Pub. No.2005003502+
Plate Mover for Crystallization Data Collection	PCT/US2002/015048 (WO02/093139) Japan +
Recombinant DNA and methods for producing thermostable enzymes	U.S. Pat. No. 6,350,591
Methods for isolation of thermophile promoters	U.S. Pat. No. 6,344,327
+ Abandoned, withdrawn or lapsed	

(v) *Domain names*

- xtalpro.com
- embios.com
- ccsbio.org
- ecrystals.org
- crystalready.com
- axasinc.com
- crystallization.net
- crystallizationdatabase.com
- crystallizationplates.com
- crystallizationresearch.com
- crystallizationrobots.com
- crystalscreens.org
- ecrystalscreens.com
- emeraldbiostructures.com
- emeraldbiosystems.com
- escreen.org
- proteincrystallization.com
- roboticcrystallization.com
- xtalscreens.com
- mpcsw2008.org
- mpcw2008.org
- gene-composer.com
- genecomposer.net
- genecomposer.org
- genecomposerlive.com
- genecomposerlive.org
- genedesigner.com
- genedesigner.net

(vi) *Software*

- Project Monitor
- CrymOn-Line
- Crystallization Screen Translators
- Scripts for Automated crystallographic refinement
- Sharepoint .Net Web applications
- GeneComposer
- Instrumentation software (Crystal Monitor, Crystal, Matrix Maker1)

SCHEDULE 1.2(r)

Persons to be Hired by Purchaser, its Affiliates or the Iceland Entities

See Appendix A attached hereto.

SCHEDULE 1.2(s)
Excluded Property and Assets

None.

SCHEDULE 4.7
Capitalization of Purchaser

The capitalization of Purchaser at the Closing shall be as follows:

	Common Shares	Series A-1 Preferred Shares	Series A-2 Preferred Shares	Series A-3 Preferred Shares	Total Outstanding Shares	% of Total Outstanding
Arch Venture Partners <i>(one fund)</i>	-	-	2,620,968	-	2,620,968	32.76%
Polaris Venture Partners <i>(multiple funds)</i>	-	-	2,620,968		2,620,968	32.76%
Illumina, Inc.	-	-	-	1,258,064	1,258,064	15.73%
deCODE holders <i>(initially decode genetics, Inc., and in any case not >35 holders)</i>	-	1,500,000	-	-	1,500,000	18.75%
Total Outstanding	-	1,500,000	5,241,936	1,258,064	8,000,000	100.00%
Common Shares Reserved for Management Incentive	2,000,000					
Total Authorized	15,000,000	1,500,000	10,200,000	1,300,000		

SCHEDULE 6.5(a)
Potentially Assigned Seller Contracts

License Agreement [relating to diabetes-related pathologies and metabolic syndrome] between deCODE genetics, Inc. and deCODE genetics, ehf, and Celera Corporation, effective April 22, 2009.

License Agreement [relating to cardiovascular and vascular diseases] between deCODE genetics, Inc. and deCODE genetics, ehf, and Celera Corporation, effective April 22, 2009.

[Collaboration and Cross-License Agreement among Hoffman-La Roche Inc., F.Hoffman-La Roche Ltd., deCODE genetics, Inc., and Islensk erf dagreining ehf., dated February 1, 1998.]

[Research Collaboration and License Agreement between Merck & Co., deCODE genetics, Inc. and deCODE genetics, ehf., effective September 26, 2002, as amended by [First Amendment?], and Second Amendment, effective September 29, 2004.]

[Agreement for the Transfer of Research Materials between The University Court of the University of Aberdeen and Grampian Health Board, and Decode Genetics Inc., dated July 10, 2009.]

[Master Project Agreement between deCODE genetics, Inc. and Fisher Clinical Services Inc., dated March 17, 2005.]

[Pharmaceutical Contract Services Agreement between deCODE chemistry, Inc. and BioConvergence LLC, effective April 20, 2007.]

[Toxicology Services Agreement between deCODE Chemistry, Inc. and Experimur, dated September 6, 2005.]

[Memorandum of Understanding among the Regents of the University of New Mexico, for its public operation known as the Health Sciences Center, deCode Genetics, Inc., and the National Center for Genome Resources, effective January 14, 2004.]

[Agreement for the Transfer of Research Materials between The University Court of the University of Aberdeen and Grampian University Hospitals NHS Trust, and Decode Genetics Inc., dated [_____] 2006.]

[Material Transfer Agreement between Drs. Richard Mains and Betty Eiper, with laboratory at University of Connecticut Health Center, and deCODE Genetics, Inc., effective December 9, 2003.]

SCHEDULE 6.8(b)

Transfer of Assets

Iceland Sub may terminate the agreement(s) set forth on Schedule 6.19 in accordance with Section 6.19 of the Agreement, including the transfers of certain assets, if any, required by the terms of the Bayer Agreement (as defined below) in connection with the termination of the Bayer Agreement pursuant to Section 11.2.2 of the Bayer Agreement.

SCHEDULE 6.8(c)

Termination of Material Contract

Although the Bayer Agreement it is not a Material Contract, Seller notes that Iceland Sub may terminate such Agreement in accordance with Section 6.19 of the Agreement.

SCHEDULE 6.8(j)
Employment Agreements

Employment agreements in effect with Daniel Hartman and all current employees of Iceland Sub (except for Kari Stefansson).

SCHEDULE 6.19
Contract Termination

License Agreement between deCODE Genetics, ehf. and Bayer Healthcare AG (“Bayer”), effective October [17/23], 2003 (the “Bayer Agreement”). Seller shall cause Iceland Sub to deliver to Bayer as promptly as possible, and in no event later than five (5) business days after the date of the Agreement, written notice of termination of the Bayer Agreement pursuant to and in accordance with Section 11.2.2 of the Bayer Agreement. Such action shall satisfy Seller’s obligation to cause the Bayer Agreement to be terminated pursuant to Section 6.19 of the Agreement.

SCHEDULE 7.2(o)
Amounts Owed to Major Creditors
(as of November 6, 2009)

	Name of Creditor	Amounts Owed
1	Illumina	\$2,990,667
2	Lýsing hf + Glitnir	1,831,188
3	S-8 ehf.	610,454
4	Nafir ehf.	235,193

SCHEDULE 7.2(e)-1

Continuing Employees of Iceland Sub

The individuals listed on Appendix A attached hereto with a location of "Iceland" are continuing employees of Iceland Sub.

SCHEDULE 7.2(o)-2
Continuing Employees of Seller and U.S. Subs

The individuals listed on Appendix A attached hereto with a location of "U.S." are employees of Seller.

APPENDIX A
Supplement to Schedules 1.2(r), 7.2(o)-1 and 7.2(o)-2

PERSONNEL LIST

Name	Location	Department	Group
Kristján A. Kristjánsson	Iceland	Blood Collection	IT
Inga Eiríksd	Iceland	Blood Collection	Nurse
Berglind Eiríksdóttir	Iceland	Blood Collection	Nurse/Reception
Agnar Helgason	Iceland	Genetics	Anthropology
Jóna Sæmundsdóttir	Iceland	Genetics	Biological Materials
Louise le Roux	Iceland	Genetics	Biological Materials
Emilía Söebeck	Iceland	Genetics	Biological Materials
Hjördís Bjarnason	Iceland	Genetics	Biological Materials
Ebba Pálsdóttir	Iceland	Genetics	Biological Materials
Sigríður Baldursdóttir	Iceland	Genetics	Biological Materials
Hildur Alma Björnsdóttir	Iceland	Genetics	Biological Materials
E. Hjaltey Rúnarsdóttir	Iceland	Genetics	Biological Materials
Ingibjörg Halldórsdóttir	Iceland	Genetics	Biological Materials
Hrefna Jóhannsdóttir	Iceland	Genetics	Biological Materials
Nína Kristinsdóttir	Iceland	Genetics	Biological Materials
Hildur B. Birnisdóttir	Iceland	Genetics	Biological Materials
Ingibjörg G. Brynleifsdóttir	Iceland	Genetics	Biological Materials
Valéria Kretovicová	Iceland	Genetics	Biological Materials
Andrea Jóhannsdóttir	Iceland	Genetics	Biological Materials
Guðbjörg K. Haraldsdóttir	Iceland	Genetics	Biological Materials
Jóhanna Stefánsdóttir	Iceland	Genetics	Biological Materials
Svanbjörg Ólafsdóttir	Iceland	Genetics	Biological Materials
Sigríður N. Sveinsdóttir	Iceland	Genetics	Biological Materials
Þórunn Rafnar	Iceland	Genetics	Cancer
Carlo Zanon	Iceland	Genetics	Cancer
Sören Basenbacher	Iceland	Genetics	Cancer
Simon Stacey	Iceland	Genetics	Cancer
Júlíus Guðmundsson	Iceland	Genetics	Cancer
Hreinn Stefánsson	Iceland	Genetics	CNS
Ómar Gústafsson	Iceland	Genetics	CNS
Sólveig Grétarsdóttir	Iceland	Genetics	CVD
Hilma Hólm	Iceland	Genetics	CVD
Unnur Styrkarsdóttir	Iceland	Genetics	CVD
Valgerður Steinþórsdóttir	Iceland	Genetics	CVD
Bragi Walters	Iceland	Genetics	CVD
Jelena P. Kostic	Iceland	Genetics	CVD
Ingileif Jónsdóttir (75%)	Iceland	Genetics	Infectious & Infl diseases

Name	Location	Department	Group
Ari Kárason	Iceland	Genetics	Infectious & Infl diseases
Hafdís Þ. Helgadóttir	Iceland	Genetics	Infectious & Infl diseases
Gerður Stefánsdóttir	Iceland	Genetics	Genetic Service facility
Stefán Þ. Pálsson	Iceland	Genetics	Genetic Service facility
Lilja B. Baldursdóttir	Iceland	Genetics	Genetic Service facility
Rut Þórarinsdóttir	Iceland	Genetics	Genetic Service facility
Sigríður E. Vilmundardóttir	Iceland	Genetics	Genetic Service facility
Katrín Óskarsdóttir	Iceland	Genetics	Genetic Service facility
Elva H. Ingvadóttir	Iceland	Genetics	Genetic Service facility
Hrafnhildur E. Halldórsdóttir	Iceland	Genetics	Genetic Service facility
Margrét Ásgeirsdóttir	Iceland	Genetics	Genetic Service facility
Andri R. Ford (60%)	Iceland	Genetics	Genetic Service facility
Silja Arnarsdóttir	Iceland	Genetics	Genetic Service facility
Einar Ö. Benjaminsson	Iceland	Genetics	Genetic Service facility
Aðalbjörg Jónasdóttir	Iceland	Genetics	GMT
Ásgeir Sigurðsson	Iceland	Genetics	GMT
Áslaug Jónasdóttir	Iceland	Genetics	GMT
Droplaug N. Magnúsdóttir (75%)	Iceland	Genetics	GMT
Steinunn Snorraddóttir (0.85)	Iceland	Genetics	GMT
Guðbjörg Þ. Örygsdóttir	Iceland	Genetics	GMT
Björgvin Richardsson	Iceland	Genetics	Grants
Margrét Jakobsdóttir	Iceland	Genetics	Grants
Iris Hrönn Guðjónsdóttir (50% in PG/CNS)	Iceland	Genetics	Grants
Magali Mouy	Iceland	Genetics	Illumina Genotyping Facility
Ólöf Ólafsdóttir	Iceland	Genetics	Illumina Genotyping Facility
Marta M. Hafsteinsdóttir	Iceland	Genetics	Illumina Genotyping Facility
Arnfríður Ragnarsdóttir (80%)	Iceland	Genetics	Illumina Genotyping Facility
Fjóla L. Magnusson	Iceland	Genetics	Illumina Genotyping Facility
Stella I. Sverrisdóttir	Iceland	Genetics	Illumina Genotyping Facility
Hákon Guðbjartsson	Iceland	Genetics	Informatics
Gisli Másson	Iceland	Genetics	Informatics/Bioinformatics
Guðbjörn F. Jónsson	Iceland	Genetics	Informatics/Bioinformatics
Eiríkur Hjartarson	Iceland	Genetics	Informatics/Bioinformatics
Gunnar Þór Sigurðsson	Iceland	Genetics	Informatics/Bioinformatics
Páll Í. Ólason	Iceland	Genetics	Informatics/Bioinformatics
Sigurjón Axel Guðjónsson	Iceland	Genetics	Informatics/Bioinformatics
Kristrún H. Helgadóttir	Iceland	Genetics	Informatics/Genealogy
Svava G. Sigurðardóttir	Iceland	Genetics	Informatics/Genealogy
Hannes Sigurðsson	Iceland	Genetics	Informatics/ITO
Örn Ásgeirsson	Iceland	Genetics	Informatics/ITO
Valgeir Þ. Halbergsson	Iceland	Genetics	informatics/ITO
Halldóra Traustadóttir	Iceland	Genetics	Informatics/ITO

Name	Location	Department	Group
Hjalti Sigurðarson	Iceland	Genetics	Informatics/ITO
Árni S. Sigurðsson	Iceland	Genetics	Informatics/ITO
Ingvar K. Árnason	Iceland	Genetics	Informatics/PM
Jónheiður Ísleifsdóttir	Iceland	Genetics	Informatics/PM
Inga H. Gunnarsdóttir	Iceland	Genetics	Informatics/PM
Herdís Eiríksdóttir	Iceland	Genetics	Informatics/PM
Vilmundur Pálmason	Iceland	Genetics	Informatics/SD
Guðmundur Fr Georgsson	Iceland	Genetics	Informatics/SD
Gunnar I. Baldvinsson	Iceland	Genetics	Informatics/SD
Þórður Kristjánsson	Iceland	Genetics	Informatics/SD
Árni Einarsson	Iceland	Genetics	Informatics/SD
Keith Roger Hayward	Iceland	Genetics	Informatics/SD
Kristleifur Kristjánsson	Iceland	Genetics	Medical Affairs
Gyða Björnsdóttir	Iceland	Genetics	Medical Affairs
Lárus J. Guðmundsson	Iceland	Genetics	Medical Affairs
Unnur Þorsteinsdóttir	Iceland	Genetics	Population genomics
Frosti Jónsson	Iceland	Genetics	Population genomics
Brynjar Viðarsson (20%)	Iceland	Genetics	Population genomics
Helga H. Knudsen	Iceland	Genetics	Population genomics
Margrét Andrésdóttir	Iceland	Genetics	Quality Assurance
Páll Gestsson	Iceland	Genetics	Robotics
Viðar B. Þorsteinsson	Iceland	Genetics	Robotics
Carl D. Tulinius	Iceland	Genetics	Robotics
Tómas Tómasson	Iceland	Genetics	Robotics
Daníel Guðbjartsson	Iceland	Genetics	Statistics
Mike Frigge	Iceland	Genetics	Statistics
Guðmar Þorleifsson	Iceland	Genetics	Statistics
Bjarni V. Halldórsson (40%)	Iceland	Genetics	Statistics
Patrick Sulem	Iceland	Genetics	Statistics
Arnaldur Gylfason	Iceland	Genetics	Statistics
Pasha Zusmanovich	Iceland	Genetics	Statistics
Stacy Steinberg	Iceland	Genetics	Statistics
Kári Stefánsson	Iceland	Overhead	CEO Office
Stella María Sigurðardóttir	Iceland	Overhead	CEO Office
Jakob Ó. Sigurðsson	Iceland	Overhead	Corporate Development
Nanna Viðarsdóttir	Iceland	Overhead	Corporate Development
Pétur Ö. Jónsson	Iceland	Overhead	Finance/Bookkeeping
Ragnheiður Kristins	Iceland	Overhead	Finance/Bookkeeping
Regína H. Sigurðardóttir	Iceland	Overhead	Finance/Bookkeeping
Anna F. Garðarsdóttir	Iceland	Overhead	Finance/Payroll
Sigríður E. Guðlaugsdóttir	Iceland	Overhead	Human resources
Kristín Þórisdóttir	Iceland	Overhead	Internal operations

Name	Location	Department	Group
Svanur Þorláksson	Iceland	Overhead	Internal operations
Guðjón Kristgeirsson	Iceland	Overhead	Internal operations
Hörður F. Magnússon	Iceland	Overhead	Internal operations
Ingólfur Ö. Birgisson	Iceland	Overhead	Internal operations
Þráinn Ársællsson	Iceland	Overhead	Internal operations/Canteen
Jónína Pálmadóttir	Iceland	Overhead	Internal operations/Canteen
Bára Snorradóttir	Iceland	Overhead	Internal operations/Canteen
Dagbjört Guðmundsdóttir	Iceland	Overhead	Internal operations/Cleaning
Anna R. Jóhannesdóttir	Iceland	Overhead	Internal operations/Cleaning
Gina B. Cuizon	Iceland	Overhead	Internal operations/Cleaning
Jón Kári Jónsson	Iceland	Overhead	Internal operations/Reception
Jóhann Hjartarson	Iceland	Overhead	Legal
Þórir Haraldsson	Iceland	Overhead	Legal
Þorlákur Jónsson	Iceland	Overhead	Legal
Ásdís Elva Aðalsteinsdóttir	Iceland	Overhead	Legal
Þórdís Gunnarsdóttir	Iceland	Overhead	Legal
Helgi Viðarsson	Iceland	Overhead	Supply Chain Management
Björn Kr. Björnsson	Iceland	Overhead	Supply Chain Management
Jeffrey Gulcher	US	Genetics	Population genomics
Stephan Barbera	US	Diagnostics	Diagnostics
Kevin Cline	US	Diagnostics	Diagnostics
Lisa Landon	US	Diagnostics	Diagnostics
Christi Blair	US	Diagnostics	Diagnostics
Augustine Kong	US	Genetics	Statistics
Richard Leach	US	Overhead	Corporate Development
Joseph Prosser	US	Overhead	Corporate Development
Daniel Sui	US	Overhead	Corporate Development